Literature DB >> 3512226

[Continuing anti-anginal effectiveness during chronic nitrate therapy in spite of the cessation of hemodynamic partial effects].

M Kaltenbach, W Schneider.   

Abstract

A decrease or actual cessation of some of the haemodynamic effects of nitrate, such as fall in blood pressure and rise in heart rate on standing upright, was observed in ten patients with coronary heart disease during a four-week period of treatment with nonretard isosorbide dinitrate, 20 and 40 mg six times daily. Disappearance of the nitrate effect was also observed by ultrasound over arterial and central venous vessels. At the same time, a crossover double-blind randomized study demonstrated that the anti-anginal action persisted. This effect is thus to be taken as preventing anginal attacks. It is concluded that chronic nitrate administration maintains its full anti-anginal action, even though haemodynamic effects are diminished or even cease completely.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3512226     DOI: 10.1055/s-2008-1068460

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

1.  Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.

Authors:  F Wagner; F Siefert; D Trenk; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil.

Authors:  M Stauch; G Grossmann; D Wanjura; W E Adam
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Nonresponsiveness to antianginal therapy--a frequent problem?

Authors:  W Schulz
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.